Search results
Showing 851 to 874 of 874 results for end of life
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Interventional procedures programme manual
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.
NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA).
NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
Today (Thursday 29 November), NICE opens a public consultation on its preliminary recommendations on the NHS use of the drug, pirfenidone (known commercially as Esbriet). The draft guidance assesses whether it should be recommended for use in people who have the lung condition, idiopathic pulmonary fibrosis.
More donor livers could be used for transplantation thanks to exciting new development, NICE says
Procedure will extend the life of a donor liver by double the length of time compared to now
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board yesterday (19 January 2022).
NICE recommend dapagliflozin for people with chronic kidney disease
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
For the last three years, NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health
Patients with rare bile duct cancer set to benefit from life extending treatment
Some people who have a rare form of bile duct cancer are set to benefit from life-extending treatment
NICE welcomes Professor Bee Wee CBE as new non-executive director
New NICE non-executive director appointment approved by Sajid Javid MP, the Secretary of State for Health and Social Care
NICE has published a guideline to help deliver personal care and practical support to older people living in their own homes. This document outlines the key recommendations for providers of home care services.